MARIETTA, Ga., Sept. 3, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the publication of another peer-reviewed scientific study in the scientific literature.
The Company's peer-reviewed article, "Cytokines in Single Layer Amnion/Chorion Allografts Compared to Multi-Layer Amnion/Chorion Allografts for Wound Healing," was electronically published in the Journal of Biomedical Materials Research Part B: Applied Biomaterials, on August 30, 2014. The paper was authored by Thomas J. Koob, PhD; Jeremy J. Lim, PhD; Nicole Zabek; and Michelle Massee. The electronic publication of the study in the Journal of Biomedical Materials Research is now available in the Wiley Online Library at http://onlinelibrary.wiley.com/doi/10.1002/jbm.b.33265/pdf
The Company's previously published analyses have determined that over 50 growth factors, chemokines, cytokines, and regulatory factors are contained in PURION® Processed dehydrated human amnion/chorion membrane (dHACM) tissue allografts, specifically EpiFix®, a bilayer laminated graft containing both amnion and chorion. The scientific study was conducted to determine the relative contribution of each layer to the overall growth factor and cytokine content, as well as biological activity in the allograft. The study compared the results to the growth factor content in five representative commercially available single layer amnion grafts.
Study Highlights include:
"Recently, there has been misinformation in the market making the generalization that all amniotic membrane grafts are similar, regardless of whether they are single layer amnion or multi-layer allografts," said Parker H. Petit, Chairman and CEO. "This study confirms that there is a substantial differentiation between multi-layer allografts with both amnion and chorion versus the single layer amnion allografts tested. This scientific study clearly demonstrates that PURION® Processed allografts with both amnion and chorion have a multiple of approximately 20 times more cytokines than the competitive single layer amnion allografts evaluated in the study."
To examine the role of tissue processing technique in cytokine retention, cytokine contents in representative dehydrated single layer wound care products (DryFlex®, AmnioExCel®, SteriShield™ Single Layer, and SteriShield II™ Dual Layer) were measured. The results demonstrated that cytokine content varied significantly among the allografts tested, and that PURION® Processed single layer amnion grafts, AmbioDry2®, contained significantly more cytokines than the other single layer products that were evaluated in the study. "AmbioDry2® is the single layer wound care product MiMedx processes for its ophthalmic partner, IOP Ophthalmics, Inc. These results suggest that, as compared to other methods of tissue processing, the proprietary PURION® Processing contributes to greater cytokine retention and the delivery of substantially more growth factors, which are known to be critically important in wound repair and tissue regeneration," commented Bill Taylor, President and COO.
The publication suggests that the retention of biologically active growth factors during processing of amniotic tissues is critically important in preserving the bioactivity of the native tissues for wound care. "The abundance of growth factors that results from combining amnion and chorion in the MiMedx dHACM allografts may contribute to these allografts being a more effective treatment in promoting the healing of refractive wounds," stated Taylor.
The ability to induce fibroblast proliferation was studied, and it was determined that both the amnion and chorion caused dermal fibroblasts to proliferate. However, the chorion per square cm was on average five times more effective at inducing proliferation. "The study determined that the predominant basis for the bioactivity is derived from the chorion. This is a clear indication that the biological activity in EpiFix® that induces fibroblast proliferation is a result of both our proprietary processing technique and the graft's multi-layer configuration with both amnion and chorion," concluded Petit.
DryFlex®and AmnioExCel® are registered trademarks, and SteriShield™ and SteriShield II™ are trademarks of their respective owners. AmbioDry2® is private labeled for, and is a registered trademark of, IOP Ophthalmics, Inc.
MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 275,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the importance of biologically active growth factors during processing of amniotic tissues in preserving the bioactivity of the native tissues for wound care and the contribution of the abundance of growth factors that results from combining amnion and chorion in the MiMedx dHACM allografts to these allografts' effectiveness in promoting the healing of refractive wounds. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the retention of biologically active growth factors during processing of amniotic tissues may prove not to be as important in preserving the bioactivity of the native tissues for wound care as the study suggests, that, in a head-to-head study, the abundance of growth factors that results from combining amnion and chorion in the MiMedx dHACM allografts may be found not to contribute to these allografts being a more effective treatment in promoting the healing of refractive wounds, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2013. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
|SOURCE MiMedx Group, Inc.|
Copyright©2014 PR Newswire.
All rights reserved